Chromadex Corp
NASDAQ:CDXC
Chromadex Corp
Net Income (Common)
Chromadex Corp
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Chromadex Corp
NASDAQ:CDXC
|
Net Income (Common)
$-4.9m
|
CAGR 3-Years
37%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Net Income (Common)
$6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
15%
|
CAGR 10-Years
17%
|
|
Danaher Corp
NYSE:DHR
|
Net Income (Common)
$4.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
|
West Pharmaceutical Services Inc
NYSE:WST
|
Net Income (Common)
$593.4m
|
CAGR 3-Years
20%
|
CAGR 5-Years
23%
|
CAGR 10-Years
18%
|
|
Agilent Technologies Inc
NYSE:A
|
Net Income (Common)
$1.2B
|
CAGR 3-Years
15%
|
CAGR 5-Years
2%
|
CAGR 10-Years
5%
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Net Income (Common)
$1.4B
|
CAGR 3-Years
69%
|
CAGR 5-Years
39%
|
CAGR 10-Years
20%
|
See Also
What is Chromadex Corp's Net Income (Common)?
Net Income (Common)
-4.9m
USD
Based on the financial report for Dec 31, 2023, Chromadex Corp's Net Income (Common) amounts to -4.9m USD.
What is Chromadex Corp's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
32%
Over the last year, the Net Income (Common) growth was 70%. The average annual Net Income (Common) growth rates for Chromadex Corp have been 37% over the past three years , 32% over the past five years .